Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis (SANDO) — Disease Characteristics Research Report

Target disease: Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO) (POLG-related ataxia-neuropathy spectrum)
Category: Mendelian (nuclear gene defect affecting mtDNA maintenance)
MONDO / Orphanet / ICD / MeSH: Not captured in the retrieved sources used for this report (see “Evidence gaps”).

Executive summary

SANDO is a clinical syndrome defined by the triad of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis/ophthalmoplegia, and is best understood today as part of the broader POLG-related ataxia-neuropathy spectrum (ANS), an umbrella term that includes disorders previously referred to as MIRAS and SANDO. (specchio2020polg1relatedepilepsyreview pages 1-3, rahman2019polgrelateddisordersand pages 4-6) The dominant disease mechanism is impaired mitochondrial DNA (mtDNA) replication/repair due to pathogenic variants in POLG, leading to mtDNA deletions and/or depletion, mitochondrial respiratory chain dysfunction (often demonstrated as COX-deficient ragged-red fibers in muscle), and progressive neuro(myopathic) degeneration. (wong2008molecularandclinical pages 1-2, mchugh2010sensoryataxicneuropathy pages 1-2) A key real-world management point is that valproic acid is contraindicated in all patients with POLG mutations due to risk of precipitating liver failure. (rahman2019polgrelateddisordersand pages 4-6) The most notable 2023–2024 development relevant to disease modification is an open-label phase 2 trial of enteral deoxycytidine/deoxythymidine (dC/dT) in POLG-related disorders (ClinicalTrials.gov NCT04802707) with encouraging interim clinical and biomarker signals. (pekeles2024safetyandefficacy pages 1-2)

Evidence map (knowledge-base ready)

Table: This table condenses the main disease-knowledge-base attributes for SANDO from retrieved evidence, including etiology, phenotype, mechanisms, diagnosis, management, and recent 2023-2024 therapeutic developments. It is useful as a structured reference for curating core facts and citations.

1. Disease information

1.1 What is the disease?

SANDO is a clinical mnemonic for a progressive neurologic syndrome characterized by sensory ataxic neuropathy, dysarthria, and ophthalmoparesis/ophthalmoplegia, and is now typically classified within the POLG-related ataxia-neuropathy spectrum (ANS). (wong2008molecularandclinical pages 1-2, specchio2020polg1relatedepilepsyreview pages 1-3) In a POLG-associated ataxia case series, SANDO was used as a diagnostic label when sensory ataxia (driven by sensory neuropathy) co-occurred with ophthalmoplegia/ptosis and bulbar involvement (dysarthria/dysphagia). (wei2023phenotypicvariabilityof pages 1-4)

Direct abstract-quotable definitions/examples (for evidentiary traceability): - POLG-associated ataxia report: “Mutations in the mitochondrial DNA polymerase gamma (POLG) are causing a wide spectrum of overlapping disorders…” and patients were “identified as sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO)”. (wei2023phenotypicvariabilityof pages 1-4) - POLG epilepsy review: “The ataxia neuropathy spectrum (ANS) includes mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO).” (specchio2020polg1relatedepilepsyreview pages 1-3)

1.2 Key identifiers

• OMIM / Orphanet / ICD-10/ICD-11 / MeSH / MONDO: Not captured in the retrieved evidence excerpts used here; therefore not reported to avoid fabrication. (rahman2019polgrelateddisordersand pages 4-6)

1.3 Synonyms and alternative names

• Ataxia-neuropathy spectrum (ANS): umbrella term including disorders previously referred to as MIRAS and SANDO. (rahman2019polgrelateddisordersand pages 4-6)
• SANDO is frequently discussed alongside the broader POLG-related disorder phenotypic spectrum (including PEO and epilepsy-dominant presentations). (rahman2019polgrelateddisordersand pages 4-6, pekeles2024safetyandefficacy pages 1-2)

1.4 Evidence source type

The SANDO-specific clinical characterization in the retrieved set is derived primarily from: - Human case reports/series (e.g., sibling pair with homozygous POLG p.A467T; muscle pathology and course). (mchugh2010sensoryataxicneuropathy pages 1-2) - Aggregated disease-level reviews and cohorts of POLG-related disorders, which provide the most robust statistics and management guidance (e.g., valproate contraindication; outcome statistics in POLG epilepsy). (rahman2019polgrelateddisordersand pages 4-6, specchio2020polg1relatedepilepsyreview pages 1-3)

2. Etiology

2.1 Disease causal factors

Primary cause: pathogenic variants in POLG, encoding the catalytic subunit of mitochondrial DNA polymerase gamma, essential for mtDNA replication and repair. (pekeles2024safetyandefficacy pages 1-2, specchio2020polg1relatedepilepsyreview pages 1-3)

Mechanistic causal chain (high-level): POLG dysfunction → impaired mtDNA replication/repair → mtDNA deletions and/or depletion → oxidative phosphorylation (OXPHOS) failure / reduced ATP production → progressive dysfunction and degeneration in high-energy tissues (nervous system, muscle). (wei2023phenotypicvariabilityof pages 1-4, wong2008molecularandclinical pages 1-2)

2.2 Risk factors

• Genetic risk: carrying pathogenic POLG variants; in many SANDO/ANS cases this is biallelic (autosomal recessive). (mchugh2010sensoryataxicneuropathy pages 1-2, rotig2024distinctclinicalcourses pages 1-2)
• Iatrogenic trigger: exposure to valproic acid (VPA) in individuals with POLG mutations can precipitate severe hepatic failure; it is explicitly contraindicated. (rahman2019polgrelateddisordersand pages 4-6)

2.3 Protective factors

No genetic or environmental protective factors specific to SANDO were identified in the retrieved evidence.

2.4 Gene–environment interactions

Strongest documented interaction in the retrieved evidence is drug-triggered toxicity: VPA exposure interacting with POLG genotype to precipitate liver failure. (rahman2019polgrelateddisordersand pages 4-6)

3. Phenotypes

3.1 Core phenotypes (with suggested HPO terms)

Below, phenotype type is indicated, followed by suggested HPO terms.

1) Sensory ataxia due to sensory neuropathy (symptom/sign)
- Key features: prominent proprioceptive loss and sensory neuropathy driving the ataxia. (wei2023phenotypicvariabilityof pages 1-4)
- Electrophysiology: absent sensory nerve action potentials (SNAPs) described in a SANDO sibling-pair case. (mchugh2010sensoryataxicneuropathy pages 1-2)
- Suggested HPO: HP:0001251 Ataxia, HP:0000762 Sensory ataxia, HP:0001278 Orthostatic hypotension (only if autonomic involvement), HP:0002936 Areflexia, HP:0003401 Axonal neuropathy, HP:0002497 Abnormal proprioception.

2) Dysarthria (symptom/sign)
- Reported as part of the defining triad and common associated feature in POLG ataxia syndromes. (specchio2020polg1relatedepilepsyreview pages 1-3, wei2023phenotypicvariabilityof pages 1-4)
- Suggested HPO: HP:0001260 Dysarthria.

3) Ophthalmoparesis / ophthalmoplegia / ptosis (clinical sign)
- CPEO-related definition: “bilateral symmetrical progressive ptosis and reduced ocular motility” (as a broader mitochondrial ophthalmoplegia construct relevant to SANDO). (ali2024mitochondrialchronicprogressive pages 1-3)
- Suggested HPO: HP:0000602 Ophthalmoplegia, HP:0000657 Oculomotor apraxia (only if present), HP:0000508 Ptosis.

3.2 Additional/common associated phenotypes (HPO suggestions)

• Dysphagia (wei2023phenotypicvariabilityof pages 1-4): HP:0002015 Dysphagia.
• Seizures / epilepsy (wei2023phenotypicvariabilityof pages 1-4, pekeles2024safetyandefficacy pages 1-2): HP:0001250 Seizures, HP:0002133 Status epilepticus.
• Myopathy / exercise intolerance (wei2023phenotypicvariabilityof pages 1-4): HP:0003198 Myopathy, HP:0003546 Exercise intolerance.
• Neuropathic pain noted as relatively frequent in POLG-related neuropathy cohorts (not necessarily SANDO-specific). (rahman2019polgrelateddisordersand pages 4-6): HP:0012531 Neuropathic pain.

3.3 Age of onset, severity, progression, frequency

• Age of onset: variable; SANDO can be adult-onset (e.g., fifth decade onset in a sibling pair). (mchugh2010sensoryataxicneuropathy pages 1-2) POLG-related disease overall ranges from childhood to late adulthood. (rahman2019polgrelateddisordersand pages 4-6)
• Progression: generally progressive; in the p.A467T sibling pair, severe disability developed over ~12 years. (mchugh2010sensoryataxicneuropathy pages 1-2)
• Frequency among affected individuals: Specific frequency of individual SANDO features was not available in the retrieved sources; however, in a POLG cohort 6 of 11 (55%) SANDO patients had POLG mutations leading to multiple mtDNA deletions. (rahman2019polgrelateddisordersand pages 4-6)

3.4 Quality-of-life impact

Direct QoL instrument data (EQ-5D/SF-36/PROMIS) were not found in the retrieved evidence; functional decline to severe disability over years is documented in at least one SANDO family report. (mchugh2010sensoryataxicneuropathy pages 1-2)

4. Genetic / molecular information

4.1 Causal genes

• POLG (primary): encodes mitochondrial DNA polymerase gamma. (pekeles2024safetyandefficacy pages 1-2)

4.2 Pathogenic variants and variant classes

• Recurrent variants across POLG disease: A467T, W748S, G848S were prevalent in a POLG-epilepsy review (74.2% of patients carried one of these across aggregated cases). (specchio2020polg1relatedepilepsyreview pages 1-3)
• SANDO-specific example (primary human case report): homozygous POLG p.A467T (c.1399G>A) in two siblings with classic SANDO triad. (mchugh2010sensoryataxicneuropathy pages 1-2)

Population frequency example (variant-specific): In a SANDO sibling-pair paper, p.A467T allele frequency in controls was reported as 0.6% (Belgian) and 0.7% (British). (mchugh2010sensoryataxicneuropathy pages 3-4)

Functional consequence example: p.A467T “results in a 96% reduction in the catalytic activity of the polymerase gamma protein.” (mchugh2010sensoryataxicneuropathy pages 3-4)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

No SANDO-specific modifier gene or epigenetic signatures were identified in the retrieved evidence.

5. Environmental information

The most salient non-genetic factor in the retrieved evidence is drug exposure: - Valproic acid can precipitate liver failure in POLG-related disease and is contraindicated. (rahman2019polgrelateddisordersand pages 4-6) Other environmental/lifestyle risk factors were not identified as SANDO-specific.

6. Mechanism / pathophysiology

6.1 Molecular pathways and cellular processes

• mtDNA replication/repair failure: POLG is essential for mtDNA replication and repair; pathogenic variants cause mtDNA maintenance defects. (pekeles2024safetyandefficacy pages 1-2)
• mtDNA deletions/depletion → OXPHOS failure: POLG mutations can lead to mtDNA depletion and deletions with downstream defective oxidative phosphorylation and reduced ATP. (wei2023phenotypicvariabilityof pages 1-4)
• Muscle mitochondrial pathology evidence: COX-deficient ragged-red fibers and multiple mtDNA deletions documented in SANDO siblings. (mchugh2010sensoryataxicneuropathy pages 1-2)

Suggested GO biological process terms: - GO:0006260 DNA replication (mitochondrial context), GO:0007005 mitochondrion organization, GO:0006119 oxidative phosphorylation, GO:0032543 mitochondrial translation (downstream consequences).

6.2 Cell types and tissue vulnerability

Evidence indicates vulnerability of high-energy tissues (nervous system, muscle) in mtDNA maintenance disorders; extraocular muscles are particularly affected in CPEO/ophthalmoplegia due to high mitochondrial demand. (ali2024mitochondrialchronicprogressive pages 1-3)

Suggested Cell Ontology (CL) terms: - CL:0000540 neuron, CL:0000100 motor neuron (as clinically relevant), CL:0000187 skeletal muscle cell.

6.3 Anatomical chain from trigger to manifestations (causal chain)

POLG pathogenic variant (germline) → reduced/aberrant pol γ activity → mtDNA deletions/depletion (especially in post-mitotic tissues) → respiratory chain dysfunction (COX deficiency) → impaired ATP generation → degeneration/dysfunction in peripheral sensory neurons (sensory neuropathy/ataxia), bulbar/brainstem circuits (dysarthria/dysphagia), and extraocular muscles (ophthalmoparesis). (wong2008molecularandclinical pages 1-2, mchugh2010sensoryataxicneuropathy pages 1-2, ali2024mitochondrialchronicprogressive pages 1-3)

7. Anatomical structures affected

7.1 Organ/system level

• Nervous system: peripheral neuropathy and central manifestations (seizures in some POLG cases). (rahman2019polgrelateddisordersand pages 4-6, pekeles2024safetyandefficacy pages 1-2)
• Skeletal muscle / extraocular muscle system: ophthalmoplegia/ptosis and myopathy features. (ali2024mitochondrialchronicprogressive pages 1-3, rahman2019polgrelateddisordersand pages 4-6)
• Liver (in POLG spectrum): vulnerability especially with VPA exposure; hepatic failure prominent in severe POLG phenotypes (Alpers and others). (rahman2019polgrelateddisordersand pages 4-6, pekeles2024safetyandefficacy pages 1-2)

Suggested UBERON terms: - Peripheral nerve (UBERON:0001021), cerebellum (UBERON:0002037; if cerebellar component), extraocular muscle (UBERON:0001631), skeletal muscle tissue (UBERON:0001134), liver (UBERON:0002107).

7.2 Subcellular localization

• Mitochondrion (matrix/nucleoid context): mtDNA maintenance and OXPHOS systems. (pekeles2024safetyandefficacy pages 1-2, zeviani2022mitochondrialneurodegeneration pages 1-2)

Suggested GO cellular component terms: - GO:0005739 mitochondrion, GO:0005759 mitochondrial matrix, GO:0005764 lysosome (only if evidence; not found here), GO:0005743 mitochondrial inner membrane.

8. Temporal development

• Onset: from childhood to adult/late-life; case evidence includes fifth-decade onset. (mchugh2010sensoryataxicneuropathy pages 1-2, rahman2019polgrelateddisordersand pages 4-6)
• Course: chronic progressive, degenerative. (pekeles2024safetyandefficacy pages 1-2)

9. Inheritance and population

9.1 Inheritance

• Many POLG-related SANDO/ANS presentations are associated with biallelic pathogenic variants (autosomal recessive). (mchugh2010sensoryataxicneuropathy pages 1-2, rotig2024distinctclinicalcourses pages 1-2)

9.2 Epidemiology

• SANDO-specific prevalence/incidence was not found in the retrieved sources.

10. Diagnostics

10.1 Clinical tests and biomarkers

• Electrophysiology: sensory neuropathy patterns (e.g., absent SNAPs). (mchugh2010sensoryataxicneuropathy pages 1-2)
• Muscle biopsy: COX-deficient ragged-red fibers; detection of multiple mtDNA deletions (long-range PCR). (mchugh2010sensoryataxicneuropathy pages 1-2)
• Blood biomarkers: GDF-15 used as a “biomarker of mitochondrial dysfunction” in the 2024 POLG dC/dT trial. (pekeles2024safetyandefficacy pages 1-2)

10.2 Genetic testing

• Gold standard: molecular confirmation of deleterious POLG variants; WES was used in a POLG-associated ataxia report and “The final diagnosis relies on the molecular finding of deleterious mutations in POLG.” (wei2023phenotypicvariabilityof pages 1-4)
• Testing caveat: lymphocyte-derived mtDNA can be less sensitive than muscle-derived tissue for detecting mtDNA deletions in POLG disease. (mchugh2010sensoryataxicneuropathy pages 3-4)

10.3 Differential diagnosis

Not exhaustively enumerated in retrieved evidence; the main differential frame is within autosomal recessive ataxias with ocular involvement and mitochondrial CPEO+ phenotypes, where POLG is a key gene to test. (ali2024mitochondrialchronicprogressive pages 1-3, lopergolo2024autosomalrecessivecerebellar pages 6-7)

11. Outcome / prognosis

SANDO-specific survival estimates were not retrieved; prognosis is typically progressive disability.

For broader POLG-related disease (important contextual statistics): - POLG-related epilepsy review (195 patients): status epilepticus in 46.4%; 5-year survival 30.2%. (specchio2020polg1relatedepilepsyreview pages 1-3) - Pediatric biallelic POLG cohort (n=40): 24/40 required urgent neurointensive care for seizures/status epilepticus, and 6/40 survived (study-specific cohort). (rotig2024distinctclinicalcourses pages 1-2)

12. Treatment

12.1 Standard-of-care management (symptomatic/supportive)

No definitive established disease-modifying therapy exists for POLG-related disease; management is typically symptomatic and multidisciplinary. (pekeles2024safetyandefficacy pages 1-2, ali2024mitochondrialchronicprogressive pages 1-3)

Critical safety guidance: - Review-level expert statement: “valproic acid (VPA) is contra-indicated in all patients with POLG mutations,” and can precipitate liver failure. (rahman2019polgrelateddisordersand pages 4-6)

Suggested MAXO terms: - MAXO:0000058 genetic testing, MAXO:0000474 physical therapy, MAXO:0000934 speech therapy, MAXO:0000747 seizure management, MAXO:0001072 avoidance of harmful medication (for VPA avoidance).

12.2 Recent developments (prioritizing 2023–2024)

(A) Phase 2 open-label dC/dT trial in POLG disorders (2024)

Study: Pekeles et al., eClinicalMedicine (Aug 2024), “Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results…”
URL: https://doi.org/10.1016/j.eclinm.2024.102740
ClinicalTrials.gov: NCT04802707 (trial registration cited in paper). (pekeles2024safetyandefficacy pages 1-2)

Key quantitative interim results in first 10 participants: - Mean NMDS improved from 27.3 to 20.7 at 6 months. (pekeles2024safetyandefficacy pages 1-2) - Mean GDF-15 decreased from 1031 pg/mL to 729 pg/mL. (pekeles2024safetyandefficacy pages 1-2) - EEG improved in 5/8 with abnormal baseline EEG. (pekeles2024safetyandefficacy pages 1-2) - Notable adverse event: diarrhea in 2 patients, self-resolving. (pekeles2024safetyandefficacy pages 1-2)

(B) POLG/TWNK fibroblast nucleoside supplementation study (2024)

Study: Dombi et al., Frontiers in Cell and Developmental Biology (Published 02 Apr 2024)
URL: https://doi.org/10.3389/fcell.2024.1260496
Key findings: In POLG1 cells, certain nucleoside combinations (notably ATGC) increased mtDNA content and significantly improved mtDNA recovery after ddC-induced depletion, with dose-dependent toxicity mitigated at lower concentrations. (dombi2024nucleosidesupplementsas pages 1-2)

13. Prevention

SANDO is genetic; therefore prevention is mainly via genetic counseling and avoidance of triggers. - Primary prevention (iatrogenic): avoid valproate in POLG mutation carriers. (rahman2019polgrelateddisordersand pages 4-6) - Reproductive prevention: not specifically described in retrieved evidence.

14. Other species / natural disease

No naturally occurring veterinary SANDO-like disease evidence was found in the retrieved sources.

15. Model organisms

• Yeast (Saccharomyces cerevisiae): highlighted as an efficient model organism for mitochondrial disease variant validation and drug screening (“drug drop test”). (magistrati2023drugdroptest pages 1-2)
• Patient-derived fibroblasts: used to assay mtDNA copy number and mitochondrial membrane potential and to test nucleoside combinations in POLG/TWNK deficiency. (dombi2024nucleosidesupplementsas pages 1-2)

Evidence gaps and limitations (important for knowledge-base curation)

1) Formal disease identifiers (MONDO, Orphanet, ICD-10/11, MeSH, and explicit OMIM for SANDO) were not present in the retrieved full-text excerpts available to the toolchain for this run; they are therefore intentionally omitted to avoid hallucination. (rahman2019polgrelateddisordersand pages 4-6) 2) Many quantitative statistics come from broader POLG cohorts (especially epilepsy-focused), not SANDO-only cohorts, reflecting the rarity of SANDO and limited cohort-size literature. (specchio2020polg1relatedepilepsyreview pages 1-3, rotig2024distinctclinicalcourses pages 1-2)

Key references (with publication dates and URLs)

• Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nat Rev Neurol. (manuscript available in PMC 2022; published 2019). https://doi.org/10.1038/s41582-018-0101-0 (rahman2019polgrelateddisordersand pages 4-6)
• Pekeles H, et al. Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders… eClinicalMedicine. Aug 2024. https://doi.org/10.1016/j.eclinm.2024.102740 (pekeles2024safetyandefficacy pages 1-2)
• Dombi E, et al. Nucleoside supplements as treatments for mitochondrial DNA depletion syndrome. Front Cell Dev Biol. 02 Apr 2024. https://doi.org/10.3389/fcell.2024.1260496 (dombi2024nucleosidesupplementsas pages 1-2)
• McHugh JC, et al. SANDO in a sibling pair with a homozygous p.A467T POLG mutation. Muscle Nerve. Feb 2010. https://doi.org/10.1002/mus.21494 (mchugh2010sensoryataxicneuropathy pages 1-2)
• Specchio N, et al. POLG1-Related Epilepsy: Review of Diagnostic and Therapeutic Findings. Brain Sciences. Oct 2020. https://doi.org/10.3390/brainsci10110768 (specchio2020polg1relatedepilepsyreview pages 1-3)
• Wong LJC, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Human Mutation. Sep 2008. https://doi.org/10.1002/humu.20824 (wong2008molecularandclinical pages 1-2)
• Ali A, et al. Mitochondrial Chronic Progressive External Ophthalmoplegia. Brain Sciences. Jan 2024. https://doi.org/10.3390/brainsci14020135 (ali2024mitochondrialchronicprogressive pages 1-3)

References

1. (specchio2020polg1relatedepilepsyreview pages 1-3): Nicola Specchio, Nicola Pietrafusa, Costanza Calabrese, Marina Trivisano, Chiara Pepi, Luca de Palma, Alessandro Ferretti, Paolo Curatolo, and Federico Vigevano. Polg1-related epilepsy: review of diagnostic and therapeutic findings. Brain Sciences, 10:768, Oct 2020. URL: https://doi.org/10.3390/brainsci10110768, doi:10.3390/brainsci10110768. This article has 15 citations.

2. (rahman2019polgrelateddisordersand pages 4-6): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 491 citations and is from a highest quality peer-reviewed journal.

3. (wong2008molecularandclinical pages 1-2): Lee-Jun C. Wong, Robert K. Naviaux, Nicola Brunetti-Pierri, Qing Zhang, Eric S. Schmitt, Cavatina Truong, Margherita Milone, Bruce H. Cohen, Beverly Wical, Jaya Ganesh, Alice A. Basinger, Barbara K. Burton, Kathryn Swoboda, Donald L. Gilbert, Adeline Vanderver, Russell P. Saneto, Bruno Maranda, Georgianne Arnold, Jose E. Abdenur, Paula J. Waters, and William C. Copeland. Molecular and clinical genetics of mitochondrial diseases due to polg mutations. Human Mutation, 29:E150-E172, Sep 2008. URL: https://doi.org/10.1002/humu.20824, doi:10.1002/humu.20824. This article has 366 citations and is from a domain leading peer-reviewed journal.

4. (mchugh2010sensoryataxicneuropathy pages 1-2): John C. McHugh, Roisin Lonergan, Rachel Howley, Killian O'Rourke, Robert W. Taylor, Michael Farrell, Michael Hutchinson, and Sean Connolly. Sensory ataxic neuropathy dysarthria and ophthalmoparesis (sando) in a sibling pair with a homozygous p.a467t polg mutation. Muscle & Nerve, 41:265-269, Feb 2010. URL: https://doi.org/10.1002/mus.21494, doi:10.1002/mus.21494. This article has 25 citations and is from a peer-reviewed journal.

5. (pekeles2024safetyandefficacy pages 1-2): Heather Pekeles, Saoussen Berrahmoune, Christelle Dassi, Anthony C.T. Cheung, Tommy Gagnon, Paula J. Waters, Ralf Eberhard, Daniela Buhas, and Kenneth A. Myers. Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in polg-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial. Aug 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102740, doi:10.1016/j.eclinm.2024.102740. This article has 15 citations and is from a peer-reviewed journal.

6. (rotig2024distinctclinicalcourses pages 1-2): Agnès Rötig, Pauline Gaignard, Giulia Barcia, Zahra Assouline, Claire-Marine Berat, Magalie Barth, Léna Damaj, Nolwenn Laborde, Marie-Thérèse Abi-Warde, Brigitte Chabrol, Pascale De Lonlay, Isabelle Desguerre, Alice Goldenberg, Emmanuel Gonzales, Emmanuel Jacquemin, Patrizia Amati -Bonneau, Dominique Bonneau, Véronique Abadie, Chrystèle Bonnemains, Pierre Broue, Anne De Saint-Martin, Philippe Durand, Alain Fouilhoux, Bertrand Isidor, Marianne Jaroussie, Guillaume Jedraszak, Hélène Maurey, Karine Mention, Sylvie S. Odent, Laurent Pasquier, Christelle Rougeot-Jung, Cyril Gitiaux, Charles-Joris Roux, Nathalie Boddaert, Arnold Munnich, and Manuel Schiff. Distinct clinical courses and shortened lifespans in childhood-onset dna polymerase gamma deficiency. Aug 2024. URL: https://doi.org/10.1212/nxg.0000000000200167, doi:10.1212/nxg.0000000000200167. This article has 10 citations.

7. (mchugh2010sensoryataxicneuropathy pages 3-4): John C. McHugh, Roisin Lonergan, Rachel Howley, Killian O'Rourke, Robert W. Taylor, Michael Farrell, Michael Hutchinson, and Sean Connolly. Sensory ataxic neuropathy dysarthria and ophthalmoparesis (sando) in a sibling pair with a homozygous p.a467t polg mutation. Muscle & Nerve, 41:265-269, Feb 2010. URL: https://doi.org/10.1002/mus.21494, doi:10.1002/mus.21494. This article has 25 citations and is from a peer-reviewed journal.

8. (wei2023phenotypicvariabilityof pages 1-4): Yanping Wei, Yuzhou Guan, and Min Qian. Phenotypic variability of polymerase gamma–associated ataxia. Unknown journal, Sep 2023. URL: https://doi.org/10.21203/rs.3.rs-3340280/v1, doi:10.21203/rs.3.rs-3340280/v1.

9. (lipponen2024mitataxhereditaryataxias pages 39-42): J Lipponen. Mitatax: hereditary ataxias in northern finland. Unknown journal, 2024.

10. (ali2024mitochondrialchronicprogressive pages 1-3): Ali Ali, Ali Esmaeil, and Raed Behbehani. Mitochondrial chronic progressive external ophthalmoplegia. Brain Sciences, 14:135, Jan 2024. URL: https://doi.org/10.3390/brainsci14020135, doi:10.3390/brainsci14020135. This article has 24 citations.

11. (kierdaszuk2020progressiveexternalophthalmoplegia pages 1-2): Biruta Kierdaszuk, Magdalena Kaliszewska, Joanna Rusecka, Joanna Kosińska, Ewa Bartnik, Katarzyna Tońska, Anna M. Kamińska, and Anna Kostera-Pruszczyk. Progressive external ophthalmoplegia in polish patients—from clinical evaluation to genetic confirmation. Genes, 12:54, Dec 2020. URL: https://doi.org/10.3390/genes12010054, doi:10.3390/genes12010054. This article has 6 citations.

12. (dombi2024nucleosidesupplementsas pages 1-2): Eszter Dombi, Tony Marinaki, Paolo Spingardi, Val Millar, Nastasia Hadjichristou, Janet Carver, Iain G. Johnston, Carl Fratter, and Joanna Poulton. Nucleoside supplements as treatments for mitochondrial dna depletion syndrome. Frontiers in Cell and Developmental Biology, Apr 2024. URL: https://doi.org/10.3389/fcell.2024.1260496, doi:10.3389/fcell.2024.1260496. This article has 13 citations.

13. (magistrati2023drugdroptest pages 1-2): Martina Magistrati, Alexandru Ionut Gilea, Maria Carla Gerra, Enrico Baruffini, and Cristina Dallabona. Drug drop test: how to quickly identify potential therapeutic compounds for mitochondrial diseases using yeast saccharomyces cerevisiae. International Journal of Molecular Sciences, 24:10696, Jun 2023. URL: https://doi.org/10.3390/ijms241310696, doi:10.3390/ijms241310696. This article has 8 citations.

14. (zeviani2022mitochondrialneurodegeneration pages 1-2): Massimo Zeviani and Carlo Viscomi. Mitochondrial neurodegeneration. Cells, 11:637, Feb 2022. URL: https://doi.org/10.3390/cells11040637, doi:10.3390/cells11040637. This article has 53 citations.

15. (lopergolo2024autosomalrecessivecerebellar pages 6-7): Diego Lopergolo, Francesca Rosini, Elena Pretegiani, Alessia Bargagli, Valeria Serchi, and Alessandra Rufa. Autosomal recessive cerebellar ataxias: a diagnostic classification approach according to ocular features. Frontiers in Integrative Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fnint.2023.1275794, doi:10.3389/fnint.2023.1275794. This article has 10 citations.

Artifacts

• Edison artifact artifact-00